Abstract
BioMarin Pharmaceutical has signed an agreement to acquire Lead Therapeutics to gain the latter’s early stage poly (ADP-ribose) polymerase (PARP) inhibitor, LT-673. BioMarin is hoping to develop the drug for the treatment of patients with rare and genetically-defined cancers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.